Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market
Vertex Pharmaceuticals (NASDAQ: VRTX) has wowed investors in recent times as it's expanded beyond its specialty area of cystic fibrosis (CF) treatment. The company launched Casgevy, a one-time curative gene editing treatment for blood disorders sickle cell disease and beta thalassemia. And Vertex recently reported positive data from trials of its pain management candidate and aims to file for regulatory review this year.
All of this is great and could result in billions of dollars in revenue. But Vertex also recently announced some news that may ensure its dominance in CF, which last year generated more than $9.8 billion in product revenue for the company. Vertex in the past said it's set to dominate the CF market through the mid-2030s, but this latest step could extend that further. That's because Vertex soon aims to file for regulatory review of a CF candidate that may even beat its biggest blockbuster. Let's find out more.
Image source: Getty Images.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
The stock is one of the favorites of our community with 44 Buy predictions and 2 Sell predictions.
With a target price of 405 € there is a slightly positive potential of 3.93% for Vertex Pharmaceuticals Inc. compared to the current price of 389.7 €.
